Browsing by Author Coates, Alan

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 131  next >
Issue DateTitleAuthor(s)Citation
2016Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, Human epidermal growth factor receptor 2-Negative early breast cancer: TEXT and SOFT TrialsCoates, Alan; Colleoni, Marco; Fleming, Gini; Francis, Prudence; Gelber, Richard; Goldhirsch, A; Gomez, Henry; Lang, Istvan; Pagani, Olivia; Pinotti, Graziella; Price, Karen N; Regan, Meredith; Tondini, Carlo; Viale, Giuseppe; Walley, Barbara; School of Public Health: Public HealthAbsolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, Human epidermal growth factor receptor 2-Negative early breast cancer: TEXT and SOFT Trials, Journal of Clinical Oncology, vol.34, 19, 2016,pp 2221-2230
2003Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breat cancer : a randomized trialCoates, Alan; Bonetti, Marco; Castiglione-Gertsch, Monica; Colleoni, Marco; Gelber, Richard D. (Prof); Goldhirsch, Aron (Prof); Nasi, M. Laura; O'Neill, Anne; Price, Karen N.; School of Public Health: Public HealthAdjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breat cancer : a randomized trial, Journal of the National Cancer Institute, vol.95,(24),2003,pp 1833-1846
2008Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trialsCoates, Alan; Clarke, M; Darby, S; Davies, C; Gelber, RD; Godwin, J; Goldhirsch, Aron (Prof); Gray, R; Peto, R; Pritchard, K I; Wood, W; School of Public Health: Public HealthAdjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials, The Lancet, vol.371, N/A, 2008,pp 29-40
2003Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IVCoates, Alan; Castiglione-Gertsch, Monica; Collins, John; Crivellari, Diana; Fey, Martin F.; Gelber, Richard D. (Prof); Goldhirsch, Aron (Prof); Lindtner, Jurji; Price, Karen N.; Rudenstam, Carl-Magnus; Senn, Hans-Jorg; School of Public Health: Public HealthAdjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV, Journal of Clinical Oncology, vol.21,(24),2003,pp 4517-4523
2014Adjuvant exemestane with ovarian suppression in premenopausal breast cancerCoates, Alan; Burstein, Harold J.; Colleoni, Marco; et al, Various; Fleming, G. F.; Gomez, Henry; Lang, Istvan; Pagani, Olivia; Perez, E. A.; Regan, Meredith M.; Tondini, Carlo; Walley, B; School of Public Health: Public HealthAdjuvant exemestane with ovarian suppression in premenopausal breast cancer, New England Journal of Medicine, vol.371, 2, 2014,pp 107-118
2002Adjuvant Immunotherapy of Patients with High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized TrialCoates, Alan; McCarthy, William; McMullen, A V E; Simes, Robert John; Thompson, John; Coventry,, B; Dillon, H; Grantley, G l; Hersey, Peter; Mcleod,, R; Sillar, R; School of Public Health: Public Health; Central Clinical School: Surgery; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: SurgeryAdjuvant Immunotherapy of Patients with High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial, Journal of Clinical Oncology, vol.20,(20),2002,pp 4181-4189
2008Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trialCoates, Alan; Altermatt, Hans J; Braye, Stephen; Castiglione-Gertsch, Monica; Del Curto, Barbara; Dell'Orto, Patrizia; Gelber, Richard D. (Prof); Goldhirsch, A; Gusterson, Barry; Henriksen, Katrine L; Lacroix-Triki, Magali; Lykkesfeldt, Anne E; Mastropasqua, Mauro G.; Mery, Eliane; Price, K. N.; Rasmussen, Brigitte B; Regan, Meredith M.; Thurlimann, Beat; Viale, Giuseppe; School of Public Health: Public HealthAdjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial, The Lancet, vol.9, N/A, 2008,pp 23-28
2016Adjuvant ovarian function suppression and cognitive function in women with breast cancerBoyle, Frances; Coates, Alan; Bellet, Meritxell; Budman, Daniel; et al, .; Francis, Prudence; Karlsson, Per; Phillips, Kelly-Anne; Puglisi, Fabio; Regan, Meredith; Ribi, Karin; Spazzapan, Simon; Zaman, Khalil; Northern Clinical School: Medicine; School of Public Health: Public HealthAdjuvant ovarian function suppression and cognitive function in women with breast cancer, British Journal of Cancer, vol.114, 9, 2016,pp 956-964
2015Adjuvant ovarian suppression in premenopausal breast cancerCoates, Alan; Bellet, Meritxell; Bonnefoi, Herve; Buchholz, Stefan; Burstein, Harold; Ciruelos, Eva; Climent, Miguel; Coleman, Richard; Colleoni, Marco; Da Prada, Gian; Davidson, Nancy; Fleming, Gini; Francis, Prudence; Gelber, Richard D. (Prof); Geyer, Charles; Giobbie-Hurder, Anita; Goldhirsch, Aron (Prof); Ingle, J.; Kerbrat, Pierre; Lang, Istvan; Maibach, Rudolph; Martino, Silvana; Price, K. N; Rabaglio-Poretti, Manuela; Regan, Meredith; Ruepp, Barbara; Viale, Giuseppe; Walley, Barbara; Winer, EP; School of Public Health: Public HealthAdjuvant ovarian suppression in premenopausal breast cancer, The New England Journal of Medicine, vol.372, 5, 2015,pp 436-446
2013Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": The CASA randomized trialCoates, Alan; Crivellari, Diana; Dellapasqua, S; et al, Various; Gianni, Lorenzo; Gray, Kathryn P; Lang, Istvan; Pinotti, Graziella; Price, Karen N; Puglisi, Fabio; Ribi, Karin; Spazzapan, Simon; School of Public Health: Public HealthAdjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": The CASA randomized trial, The Breast, vol.22, 2, 2013,pp 130-137
2016Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trialCoates, Alan; Bellet, Meritxell; Bernhard, Jurg; Burstein, Harold J.; Ciruelos, Eva; et al, Various; Francis, Prudence; Lluch, Ana; Luo, Weixiu; Pavesi, Lorenzo; Ribi, Karin; School of Public Health: Public HealthAdjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial, Journal of Clinical Oncology, vol.34, 14, 2016,pp 1601-1610
2016Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trialCoates, Alan; Bellet, Meritxell; Bernhard, Jurg; Burstein, Harold J.; Ciruelos, Eva; et al, Various; Francis, Prudence; Lluch, Ana; Luo, Weixiu; Pavesi, Lorenzo; Ribi, Karin; School of Public Health: Public HealthAdjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial, Journal of Clinical Oncology, vol.34, 14, 2016,pp 1601-1610
2001Adjuvant therapy for very young women with breast cancer: need for tailored treatments.Coates, Alan; Bryant,, J; Castiglione-Gertsch, Monica; Gelber, Richard D. (Prof); Gelber, Shari; Goldhirsch, Aron (Prof); Gray, R; Green, S; Yothers, G; School of Public Health: Public HealthAdjuvant therapy for very young women with breast cancer: need for tailored treatments., Journal of the National Cancer Institute, vol.30,(N/A),2001,pp 44-51
2013Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trialsCoates, Alan; Colleoni, Marco; Fleming, Gini; Francis, Prudence; Gelber, Richard; Goldhirsch, Aron (Prof); Maibach, Rudolph; Pagani, Olivia; Price, Karen; Rabaglio, Manuela; Regan, Meredith; Ruepp, Barbara; Walley, B; School of Public Health: Public HealthAdjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials, The Breast, vol.22, 6, 2013,pp 1094-1100
2010Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancerCoates, Alan; Cole, Bernard; Crivellari, Diana; Gelber, Richard; Gelber, Shari; Goldhirsch, A; Holmberg, Stig B.; Paridaens, Robert; Price, Karen N.; Thurlimann, B.; School of Public Health: Public HealthAdjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer, Breast Cancer Research and Treatment, vol.123, 1,pp 303-310
2010Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.Coates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; et al, various; Giobbie-Hurder, Anita; Gusterson,, B; Maiorano, Eugenio; Mallon, Elizabeth; Mastropasqua, Mauro G.; Sonzogni, A; Viale, Giuseppe; School of Public Health: Public HealthAdverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer., Annals of Oncology, vol.21, 2,pp 245-254
2011Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 studyCoates, Alan; Chirgwin, Jacquie H; Colleoni, Marco; Forbes, John F.; Gelber, Richard D. (Prof); Giobbie-Hurder, Anita; Goldhirsch, Aron (Prof); Lang, Istvan; Mauriac, L; Mouridsen, Henning; Paridaens, R.J.; Pienkowski, Tadeusz; Price, Karen N.; Regan, Meredith M.; Smith, Ian (Prof); Thurlimann, Beat; Wardley, Andrew; School of Public Health: Public HealthAnalyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study, Journal of Clinical Oncology, vol.29, 9, 2011,pp 1117-1124
2010Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancersCoates, Alan; Accortanzo, Valeria; Allin, Elena; Arisio, Riccardo; Bussolati, Gianni; Castellano, Isabella; Chiusa, Luigi; Donadio, Michela; Durando, Antonio; Vandone, Anna Marie; Viale, Giuseppe; School of Public Health: Public HealthAndrogen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers, Breast Cancer Research and Treatment, vol.124, 3,pp 607-617
2008Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study GroupCoates, Alan; Aebi, Stefan; Byrne, Michael J.; Cole, Bernard; Colleoni, Marco; Crivellari, Diana; et, al; Gianni, Lorenzo; Holmberg, Stig B.; Panzini, Ilaria; Snyder, Raymond; School of Public Health: Public HealthAnemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group, Supportive Care in Cancer, vol.16,(1),2008,pp 67-74
2016Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to VCoates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; Forbes, John F.; Gelber, Richard; Gianni, Lorenzo; Goldhirsch, Aron; Karlsson, Per; Price, Karen; Sun, Zhuoxin; Thurlimann, B.; School of Public Health: Public HealthAnnual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to V, Journal of Clinical Oncology, vol.34, 9, 2016,pp 927-935